Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Month 48 Phosphatemia (Z-score)Mean ± SDSEMMedianMin-maxN = 23-0.7 ± 0.70.1-0.7-2.0-1.0N = 23-1.4 ± 1.10.2-1.2-3.5-0.4p = 0.005bALPs (Z-score)Mean ± SDSEMMedianMin-maxN = 90.9 ± 2.20.7-0.0-1.3-4.9N = 90.7 ± 1.30.40.3-0.6-3.0 p = NS 25-OH-vit-D (nmol/L)Mean ± SDSEMMedianMin-maxN = 955.0 ± 33.711.241.025.0-127.3N = 951.0 ± 19.26.452.033.0 to 93.0 p = NS 1-25-OH-vit-D (pmol/L)Mean ± SDSEMMedianMin-maxN = 9164.6 ± 54.118.0172.0100.0-230.0N = 9158.6 ± 36.312.1159.0111.0-200.0 p = NS PTH (ng/L)Mean ± SDSEMMedianMin-max N patients in normal range (%) N = 1515.6 ± 8.22.1311.78.2 to 37.215 (100%)N = 1816.6 ± 6.61.5516.67.2 to 37.818 (100%)NA B22CS baseline EoS Nephrocalcinosis N patients (%)N = 2925 (86%)N = 2523 (92%)NA Nephrolithiasis N patients (%)N = 296 (21%)N = 2511 (44%)NASibnayal®dose (CK-BK PR, mEq/kg/d)Mean ± SDSEMMedianMin-maxN = 293.4 ± 1.70.33.21.1-8.0N = 262.3 ± 1.10.22.11.0-5.11-25OHvitD, 1-25dihydroxyvitamin D; 25OHvitD, 25hydroxyvitamin D; ACCP, amorphous carbonated calcium phosphate; bALP, blood alkaline phosphatase; BMD: bone mineral density; BMI, body mass index; EAS, estimated adult stature; eGFR, estimated glomerular filtration rate; EoF, End of Followup; EoS, End of Study; KDIGO, Kidney Disease: Improving Global Outcomes; Max, maximum; Min, minimum; N, number of patients; NS, nonsignificant; PTH, parathyroid hormone; SD, standard deviation; SEM, standard error of the mean; SoC, standard of care; TMP/GFR, ratio of renal tubular reabsorption of phosphorus to glomerular filtration rate; UCa/UCi, urinary ratio of calcium/citrate; UCa/UCr, urinary ratio of calcium/creatinine; UCi/UCr, urinary ratio of citrate/creatinine; UpH, urinary pH, CK-BK PR, potassium citrate and potassium bicarbonate prolonged release
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Open-label reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
All patients were previously included in the pivotal B21CS study, so were already receiving Sibnayal® when included in B22CS open-label follow-up study.
Source: Abstract.
All patients were previously included in the pivotal B21CS study, so were already receiving Sibnayal® when included in B22CS open-label follow-up study.
Source: Abstract.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
6-year treatment follow-up with an extended-release alkaline formulation (Sibnayal®) in primary distal renal tubular acidosis
Study design awaiting verification · Orphanet Journal of Rare Diseases · 2025
Original publication title
6-year treatment follow-up with an extended-release alkaline formulation (Sibnayal®) in primary distal renal tubular acidosis
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Distal renal tubular acidosis (dRTA) is a rare disease characterized by hyperchloremic metabolic acidosis affecting growth, bone and kidney health.
Source: BackgroundAbstract: What methods does the paper describe?
The aim of B22CS study was to evaluate long-term safety and efficacy (anthropometric/pubertal, tubular damages/kidney function, bone biomarkers, compliance assessments) of Sibnayal®, a prolonged-release alkalinizing formulation with twice daily dosing, in children and adults with dRTA. All patients were previously included in the pivotal B21CS study, so were already receiving Sibnayal® when included in B22CS open-label follow-up study.
Source: MethodsAbstract: Results
A total of 30 patients with primary dRTA (mean age:10.6 ± 6.0 years) entered this long-term study (average of 6 years). At inclusion, most patients had adequate metabolic control, normal kidney function and height. Sibnayal® was well tolerated over the study duration.The most frequent adverse event was hypovitaminosis D (13 patients). Causality to treatment was reported for only 4% of all TEAEs (6 patients) and were mostly gastrointestinal. All adverse events resolved without treatment discontinuation. Sibnayal® allowed a sustained control of metabolic acidosis as plasma bicarbonate level was 22.0 ± 3.2 mmol/L at baseline versus 22.6 ± 2.5 mmol/L at the End of Follow-up (EoF), p = NS.
From baseline to EoF, mean Z-score height significantly increased (-0.6 ± 1.0 to -0.3 ± 1.0, p = 0.03), without significant change in weight and body mass index. Kidney function remained stable from baseline to EoF: estimated glomerular filtration rate = 105 ± 17 and 104 ± 20 mL/min/1.73m2, respectively, p = NS. Urinary ratios: Calcium/Creatinine (UCa/UCr), Citrate/Creatinine (UCi/UCr), Calcium/Citrate (UCa/UCi) were not significantly different between baseline and EoF (p = NS). Mean lumbar bone mineral density Z-score significantly increased from baseline (-1.1 ± 1.0) to EoF (-0.8 ± 1.0), p = 0.005, with significant improvement between baseline and EoF in pre: and post-pubertal patients (p = 0.035 and p < 0.001, respectively), whilst it was maintained in pubertal patients (p = NS).
Source: ResultsAbstract: Conclusion
Long-term data support the good safety and efficacy profile of Sibnayal® in the treatment of dRTA with adequate control of metabolic acidosis, stable kidney function and significant positive long-term clinical outcomes.
Source: ConclusionAuthors’ abstract
Background
Distal renal tubular acidosis (dRTA) is a rare disease characterized by hyperchloremic metabolic acidosis affecting growth, bone and kidney health.
Methods
The aim of B22CS study was to evaluate long-term safety and efficacy (anthropometric/pubertal, tubular damages/kidney function, bone biomarkers, compliance assessments) of Sibnayal®, a prolonged-release alkalinizing formulation with twice daily dosing, in children and adults with dRTA. All patients were previously included in the pivotal B21CS study, so were already receiving Sibnayal® when included in B22CS open-label follow-up study.
Results
A total of 30 patients with primary dRTA (mean age:10.6 ± 6.0 years) entered this long-term study (average of 6 years). At inclusion, most patients had adequate metabolic control, normal kidney function and height. Sibnayal® was well tolerated over the study duration.The most frequent adverse event was hypovitaminosis D (13 patients). Causality to treatment was reported for only 4% of all TEAEs (6 patients) and were mostly gastrointestinal. All adverse events resolved without treatment discontinuation. Sibnayal® allowed a sustained control of metabolic acidosis as plasma bicarbonate level was 22.0 ± 3.2 mmol/L at baseline versus 22.6 ± 2.5 mmol/L at the End of Follow-up (EoF), p = NS.
From baseline to EoF, mean Z-score height significantly increased (-0.6 ± 1.0 to -0.3 ± 1.0, p = 0.03), without significant change in weight and body mass index. Kidney function remained stable from baseline to EoF: estimated glomerular filtration rate = 105 ± 17 and 104 ± 20 mL/min/1.73m2, respectively, p = NS. Urinary ratios: Calcium/Creatinine (UCa/UCr), Citrate/Creatinine (UCi/UCr), Calcium/Citrate (UCa/UCi) were not significantly different between baseline and EoF (p = NS). Mean lumbar bone mineral density Z-score significantly increased from baseline (-1.1 ± 1.0) to EoF (-0.8 ± 1.0), p = 0.005, with significant improvement between baseline and EoF in pre: and post-pubertal patients (p = 0.035 and p < 0.001, respectively), whilst it was maintained in pubertal patients (p = NS).
Conclusion
Long-term data support the good safety and efficacy profile of Sibnayal® in the treatment of dRTA with adequate control of metabolic acidosis, stable kidney function and significant positive long-term clinical outcomes.
Supplementary Information
The online version contains supplementary material available at 10.1186/s13023-025-03953-4.
Publication and source details
Original title: 6-year treatment follow-up with an extended-release alkaline formulation (Sibnayal®) in primary distal renal tubular acidosis
Aurélia Bertholet-Thomas; Aurélie De Mul; Julie Bernardor; Gwenaëlle Roussey-Kesler; Ludmila Podracka; Robert Novo; François Nobili; Bertrand Knebelmann; Jérôme Harambat; Emilija Golubovic; Olivia Boyer; Massimo Di Maio; Mathilde Cailliez; Véronique Baudouin; Laure Chidler; Véronique Leblanc; Justine Bacchetta
Orphanet Journal of Rare Diseases · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T03:25:54.849721+00:00
DOI: 10.1186/s13023-025-03953-4 · PMC12351860